Council of Scientific and Industrial Research

Department of Biotechnology Department of the Government of India

Visva-bharati

Samir Bhattacharya

Santu Bandyopadhyay

Bikash Chandra Pal

Keshab Chandra Roy

Mitali Ray

Goutam Banerjee

Tanusree Biswas

Mohua Mukherjee

Ranjan Bhadra

Sib Sankar Roy

Alok Pal

Malabika Datta

Paruchuri Gangadhar Rao

Suchandra Goswami

Aditya Konar

Pratap Kumar Das

Krishna Das

Subrata Dasgupta

Bikas Chandra Pal

Arun Bandyopadhyay

Nabin Chandra Barua

Mitali Roy

Sukdeb Banerjee

Niranjan Prasad Sahu

Swapan Kumar Mandal

Suman Dasgupta

Tanushree Biswas

Bir Bhanu Giri

Santu Bandopadhyay

Asok Kumar Bhattacharyya

Shampa Biswas

Debleena Dey

Suchandra Sett

Gautam Bandyopadhyay

Chiranjib Pal

Monidipa Gosh

Mantu Bhuyan

Pranab Ram Bhattacharyya

Pranab Kumar Baruah

Sushmita Bhattacharya

Rakesh Kundu

Priyajit Chatterjee

Soma Seal

Shelley Bhattacharya

Sudipta Moitra

Sandeep Mukherjee

The present invention relates to a synergistic pharmaceutical composition comprising Compound C2 (Neo-isopulegol), C3 (Iso-pulegol) and C4 (Citronellol) derived from herbal seed extract ofuseful for the treatment of lung cancer. The present invention also relates to the activity of compounds C2 or C3 or C4 either alone or in combination in killing of A549 lung cancer cells.

Synergistic pharmaceutical composition useful for the treatment of lung cancer

A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract ofby HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination.

Herbal composition for treating CD33+ acute and chronic myeloid leukemia and a method thereof

Described is an in vitro method for developing dendritic Langerhans type cells, for use in immunotherapy against cancer or infectious diseases and enhancement of graft survival in mammals. The method includes the steps of: culturing cells selected from peripheral blood monocytes and bone marrow cells in a medium containing platelets obtained from the same species or phylogenetically close species; and incubating the culture at 30 to 40&#xb0; C. for a period sufficient to enable formation of mature dendritic Langerhans type cells.

In vitro method to generate dendritic Langerhans type cells

The present invention provides a method of treating acute and chronic myeloid leukemia (AML & CML) and lymphoid leukemia, said method comprising administering a pharmaceutical composition comprising pharmaceutically effective amount of chlorogenic acid (CA) and 3-o-p-Coumaryl quinic acid (PCQ) isolated from any plant parts ofor any other source, both individually or in a synergistic combination optionally along with pharmaceutically acceptable additives.

Synergistic composition for treating leukemia

A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water: methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract ofby HPLC, with retention time of 3.6 and 24.0 minutes respectively, with said fractions used both individually, and in combination, and a composition comprising the said fraction nos. 1 and 9.

A pharmaceutical composition comprising an effective amount of an extract or lyophilized extract or at least one bioactive fraction obtained from the plantalong with one or more pharmaceutically acceptable additives/carriers for treating ulcer caused by the conditions such as stress induced ulcer, peptic ulcer, cold restraint induced ulcer, drug induced ulcer and acid induced ulcer, also used as specific inhibitor of gastric H, K-ATPase and anti-activity.

[object Object]

The present invention relates to a method of preventing and/or treating diabetes type 2, also, it relates to a method of augmenting Glut4 phosphorylation and Glut4 translocation to a target cell membrane to enhance insulin signal in a signal transduction pathway; further, it relates to a simplified and inexpensive process of obtaining extract and thereafter selectively, its active n-butanol fraction and active molecule Lupinoside PA (LPA), useful in preventing and/or treating diabetes type 2; and lastly, a pharmaceutical composition thereof.

Herbal extract and compound lupinoside and its analogues as anti-diabetic type II drugs from plant Pueraria tuberosa

The present invention provides for the use of oil of clove which causes instant immobilization of human spermatozoa both in presence of seminal fluid as well as in presence of female reproductive tract fluids, including uterine components and cervical mucus and also be useful for treating and/or preventing the common vaginal infections.

Composition having antibacterial and antifungal properties

The present invention relates to an adipocyte Insulin adpInsl with Insulin A and B chains of SEQ ID Nos. 1 and 2, a effective method of treating type 2 diabetes in a subject using adipocyte insulin, said method comprising steps of administering the insulin to a diabetic intraperitoneally, an Insulin gene of SEQ ID No. 3, a process of isolating protein Insulin from the adipocytes of the Carp, said method comprising steps of reverse transcripting RNA of adipocytes to obtain cDNA, using oligonucleotide primers of SEQ ID Nos. 5 and 6 to identify AdpInsl gene from cDNA, and deducing amino acid sequence from cDNA to obtain protein Insulin, and an adipocyte of Catla Catla useful for producing the said Insulin.

Adipocyte Insulin adpinsl with Insulin A and B chains and an effective method of treating type 2 diabetes in a subject using adipocyte insulin

This invention relates to use of betel leaf extract to induce IFN&#x3b3; from human peripheral blood mononuclear cells and as a Thtype immuno modulator, wherein the said method comprises the steps of, preparing water extract of betel leaf, preparation of human peripheral blood mononuclear cells, incubation of hPBMC with betel leaf extract for a period of 18&#x2013;48 hours, extraction of RNA for cytokine specific RT-PCR or for flow cytometry for the detection of intracellular cytokine protein, subjecting RNA for RT-PCR to obtain PCR products using IFN&#x3b3; specific known primers, and enhancement of IFN&#x3b3; as reflected by IFN&#x3b3; specific band.

Use of betel leaf extract to induce IFN-gamma production from human peripheral blood T cells and as a Th1 type immunomodulator

A new herbal-based composition and method for treatment of CD33+ acute and chronic myeloid leukemia byleaf extracts, and to provide a process for the isolation of active fractions from leaves or any other plant parts ofto treat CD33+ AML and CML with a simplified method of isolation of active components from all plant parts ofpossessing biological activities relevant to the treatment of CD33+ AML and CML.

Herbal-based composition for treating acute and chronic myeloid leukemia

A method of treating CD33+ acute and chronic myeloid leukemia in animals including humans, using fraction nos. 1 and 9 obtained from water:methanol fraction by column chromatography, with ratio of water and methanol ranging between 1:5 to 5:1, wherein said water:methanol fraction is obtained from the polar extract ofby HPLC, with retention time of 3.6 and 24.0 minutes respectively, with the fractions used both individually, and in combination, and a composition including the fraction nos. 1 and 9.

This invention relates to an herbal composition for the treatment and remedy of bronchial respiratory difficulties, more particularly this invention describes the process of separation, physicochemical characterization and biological response evaluation of active components obtained from extracts of any plant parts including leaves, barks, roots and seeds of plants and in order to establish their role on the treatment and remedy of bronchial respiratory troubles.

HERBAL COMPOSITION OF BLEND OF ACTIVE COMPONENTS PREPARED FROM MURRYA KOENIGII AND PIPER BETLE USEFUL FOR BLOCKING OF 5 LIPOXYGENASE ACTIVITY LEADING TO THE INHIBITION OF LEUKOTRIENE SYNTHESIS, SUPPRESSION OF INTERLEUKIN-4 PRODUCTION, AND ENHANCEMENT OF GAMMA INTERFERON RELEASE

This invention relates to method of treating visceral leishmaniasis or kala-azar by administering effective amount of betel leaf extract or lyophilized extract together with or associated with an additive and a composition comprising betel leaf extract with a pharmaceutically acceptable additive.

Anti-leishmanial activity of betel leaf extract

Growing community of inventors

Calcutta, India

Samir Bhattacharya